Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00762164 · ClinicalTrials.gov registry record · Phase 4

Comparison of the Effect of Vytorin 10/80 Tablet Split Into 4 and Simvastatin 20 Milligrams on Low-density Lipoprotein (LDL) Cholesterol

A Phase 4 study of Hypercholesterolemia, sponsored by Bronx VA Medical Center.

Completed
Registry status
Phase 4
Development phase
34
Enrollment target
1
Study location

NCT00762164 is a Phase 4 study of Hypercholesterolemia that has completed, run by Bronx VA Medical Center. The registered enrollment target is 34 participants, below the 816-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00762164, a Phase 4 study of Hypercholesterolemia, has completed, sponsored by Bronx VA Medical Center.

COMPLETED
Registry status
Phase 4
Development phase
34 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to compare the efficacy of a Vytorin 10/80 tablet, an approved agent for the treatment of elevated LDL cholesterol which combines the cholesterol absorption inhibitor Ezetimibe 10 mg and simvastatin 80 mg, when split into 4 using a tablet splitter, versus a whole simvastatin 20 milligram tablet.

Conditions Studied

Interventions

  • DRUG Simvastatin
  • DRUG Vytorin

Study Locations (1)

New York

  • Bronx VA Medical Center - The Bronx

Trial Details

FieldValue
Enrollment Target 34 participants
Start Date 2007-03
Est. Completion 2009-05
Phase Phase 4

Sponsor

Bronx VA Medical Center

13 total trials

What the Registry Record Tells You About NCT00762164

The ClinicalTrials.gov registry entry for NCT00762164 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 816-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (96% lower). The listed sponsor is Bronx VA Medical Center, which has 13 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hypercholesterolemia appearing as the primary indexed condition, and to 2 interventions - of which Simvastatin is the first listed.

NCT00762164 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT00762164 about?

NCT00762164 is a clinical study titled "Comparison of the Effect of Vytorin 10/80 Tablet Split Into 4 and Simvastatin 20 Milligrams on Low-density Lipoprotein (LDL) Cholesterol". The purpose of this study is to compare the efficacy of a Vytorin 10/80 tablet, an approved agent for the treatment of elevated LDL cholesterol which combines the cholesterol absorption inhibitor Ezetimibe 10 mg and simvastatin 80 mg, when split into 4 using a tablet splitter, versus a whole simvast...

What is the current status of trial NCT00762164?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 34 participants. The study started on 2007-03. Estimated completion is 2009-05.

What conditions does trial NCT00762164 study?

This clinical trial studies the following conditions: Hypercholesterolemia.

What interventions are being tested in trial NCT00762164?

The interventions under investigation include: Simvastatin (DRUG), Vytorin (DRUG).

Who is sponsoring clinical trial NCT00762164?

This trial is sponsored by Bronx VA Medical Center, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00762164 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hypercholesterolemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.